Navigation Links
BioDelivery Sciences Announces Completion of Recruitment in BEMA Buprenorphine Phase 3 Chronic Pain Study
Date:4/5/2011

RALEIGH, N.C., April 5, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today completion of enrollment in its Phase 3 clinical trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain.

(Logo: https://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"The completion of enrollment in our Phase 3 efficacy study marks another very important milestone in our clinical development program for BEMA Buprenorphine in the management of chronic pain," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are very pleased to have achieved our aggressive recruitment and enrollment goals.  This milestone keeps us on target for reporting top-line study results in the third quarter of this year and is consistent with a timeline that would allow for a New Drug Application (NDA) to be filed in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  The company believes that buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  In addition, BEMA Buprenorphine has the potential to be the first oral transmucosal form of buprenorphine to treat chronic pain in the U.S.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

Additional Information on Phase 3 Study Design (BUP-301)

This Phase 3 trial of BEMA Buprenorphine (referred to as BUP-301) is
'/>"/>

SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. BioDelivery Sciences to Present at the 23rd Annual ROTH OC Growth Stock Conference
2. BioDelivery Sciences Confirms 505(b)(2) Pathway for BEMA Buprenorphine/Naloxone for Opioid Dependence Following FDA Meeting
3. BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
4. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
5. TCG Lifesciences Expands Pharmaceutical, Biotechnology Research Initiatives with CAS SciFinder®
6. Sofie Biosciences Launches a High Performance, Benchtop Preclinical PET System Using New Generation Detector Technology
7. Caliper Life Sciences Launches Novel COX-2 Probe to Enable Personalized Medicine Research
8. Regado Biosciences, Inc. Presents Results of the RADAR Phase 2b Clinical Trial of its REG1 Anticoagulation System
9. Neurocrine Biosciences to Present at the 10th Annual Needham Healthcare Conference
10. Regado Biosciences to Present at the Needham & Companys 10th Annual Healthcare Conference in New York City
11. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... 24, 2014  Surgical Theater, LLC, announced today that ... th opening of Europe,s ... "C. Besta." The SuRgical Planner (SRP) and the Surgical ... event for their 3D navigation and augmented reality capabilities ... , Professor and Chair, Department of Neurosurgery at Mount ...
(Date:11/24/2014)...  Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today ... board of directors and from his positions as chairman and ... serving as the company,s president and chief operating officer, will ... board of directors.  Gary Lyons , a member of ... Gower is expected to remain an employee until the end ...
(Date:11/24/2014)... Nov. 24, 2014  Pifflers United Chronic and ... the release of results of a study of ... the self-management of fibromyalgia pain. The results demonstrated ... pain, very significant clinically meaningful pain reduction can ... members with fibromyalgia used ActiPatch® for 7 days ...
Breaking Medicine Technology:Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Rigel Announces Executive Management Changes 2Rigel Announces Executive Management Changes 3Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3
... the ASSERT Trial Presented at EULAR, BARCELONA, ... today at the European League Against Rheumatism ... patients with,ankylosing spondylitis (AS) who received REMICADE(R) ... spinal,mobility. In addition, REMICADE-treated patients showed sustained,reductions ...
... from 741-patient trial show those treated with,Prexige experienced ... , * Many patients with osteoarthritis also have ... can impact,cardiovascular risk[2],[3] , * Prexige approved in ... US for use in osteoarthritis patients , BASEL, ...
Cached Medicine Technology:Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 2Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 3Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 4Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 5Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 6Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 7Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 8Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 9Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 10Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 11Remicade Two Year Data in Ankylosing Spondylitis Show Improvement,in Spinal Mobility and Spinal Inflammation 12Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 2Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 3Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 4Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 5Prexige Study Shows Significantly Less Impact on Blood Pressure,Than Ibuprofen in Osteoarthritis Patients with Controlled,Hypertension 6
(Date:11/24/2014)... PA (PRWEB) November 24, 2014 ... Nataliya Ternopolska, MD has joined The Neurology Group ... Health’s Multiple Sclerosis Center. , A graduate of ... in Neurology at Albert Einstein Medical Center in Philadelphia ... Judith Jaffe Multiple Sclerosis Center at Weill Cornell Medical ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Olaparib functions ... polymerase (PARP) and is one of the first PARP ... to creating some types of melanoma, and are often ... also sometimes gives their malignancies a exclusive weaknesses, as ... to fix their DNA and allow them to proceed ...
(Date:11/24/2014)... SWAccessControl.com has recently released a new collection ... the company is a leading online supplier in the international ... available at discounted prices, up to 30% off. , “We ... This time, all of our items are offered at low ... so I have confidence in our fresh assortment. You will ...
(Date:11/24/2014)... CA (PRWEB) November 24, 2014 SafeHandles™ ... episode of Innovations with Ed Begley Jr, airing via ... was created to provide a passive, non-invasive, replaceable, and ... how SafeHandles™ incorporates custom-fit shrinkable sleeves and adhesives to ... , “At the core of SafeHandles is the ...
(Date:11/24/2014)... (PRWEB) November 24, 2014 Dr. Michael ... Fertility Center, recently appeared on NBC to discuss egg freezing ... freezing has been trending in the news recently, with new ... procedure for women. , “[The companies] see it ... are on a career hot path.” Says Dr. Kettel. , ...
Breaking Medicine News(10 mins):Health News:Nataliya Ternopolska Named Associate Medical Director of Abington Health’s Multiple Sclerosis Center 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:SWAccessControl.com Is Happy To Release New Range Of Magnetic Locks 2Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 2Health News:Dr. Michael Kettel of San Diego Fertility Center Gives “An Inside Look at Freezing Eggs” on NBC 3
... One way to respond to this is to blame the victimto ... another common response, according to a new study published in ... The researchers found that people who believe in justice in the ... meaning. "A lot of the time when people see ...
... (BUSM) have been awarded a five-year, $2 million grant ... Network (EDRN), as well as a four-year, $1.3 million ... will allow the scientists to develop novel and complementary ... patients. The grant from NCI will support ...
... in French . , MONTREAL, December 14, 2010 ... babies learn to recognize the sound of their parents, voice and ... between parents and newborns admitted to the intensive care unit can ... relationship. , Jan Lariviere, a nurse in the neonatal clinic and ...
... TUESDAY, Dec. 14 (HealthDay News) -- Prayer can help ... emotions by using coping methods such as venting, a ... people in abusive relationships who were interviewed by Shane ... Wisconsin, Madison. The racially diverse participants came from different ...
... , TUESDAY, Dec. 14 (HealthDay News) -- Most of the ... is funded by states, not the federal government, a new ... the extent to which states prioritized human embryonic stem cell ... could likely have been funded under federal government guidelines established ...
... collaboration between researchers at the Salk Institute for Biological ... the tumor suppressor p53, long thought of as the ... cancer-causing mutations. It may also prevent established cancer cells ... serving as a "Guardian against Genome Reprogramming." The ...
Cached Medicine News:Health News:People who believe in justice also see a victim's life as more meaningful after tragedy 2Health News:Boston University School of Medicine awarded grants to improve early detection of lung cancer 2Health News:Once upon a time in the Intensive Care Unit ... 2Health News:Prayer May Help Victims of Domestic Abuse 2Health News:States Now Fund Most Embryonic Stem Cell Research in U.S. 2Health News:The stemness of cancer cells 2Health News:The stemness of cancer cells 3
This ELISA test is used for the detection and semi-quantitation of lgG antibobies to proteinase 3(pr3) in human sera, as an aid to the diagnosis of wegener s granulomatosis....
... involved in the control of the growth ... which synthesize and secrete male and female ... FSH is controlled by these sex hormones ... FSH Quantitative Test Kit is based on ...
... Our Class II Direct to High Res SSP kits ... a single tray. Locus specific typing on a single ... , Straight from genomic DNA to high resolution ... Allele level typing with a single tray , Unique ...
... to High Res SSP kits provide high resolution typing ... specific typing on a single tray reduces QC and ... genomic DNA to high resolution results, no need for ... a single tray , Unique reaction pattern for most ...
Medicine Products: